COAG (Hemab Therapeutics Holdings) Days Inventory: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
12 GF Score
Price $41.19
! 1 Warning Sign
View Full Analysis

What is Hemab Therapeutics Holdings Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Hemab Therapeutics Holdings's Average Total Inventories for the three months ended in Jun. 2026 was $0.00 Mil. Hemab Therapeutics Holdings's Cost of Goods Sold for the three months ended in Jun. 2026 was $0.08 Mil. Hence, Hemab Therapeutics Holdings's Days Inventory for the three months ended in Jun. 2026 was 0.00.

The historical rank and industry rank for Hemab Therapeutics Holdings's Days Inventory or its related term are showing as below:

COAG's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 184.675
* Ranked among companies with meaningful Days Inventory only.

Hemab Therapeutics Holdings's Days Inventory stayed the same from . 20 (0.00) to Jun. 2026 ().

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Hemab Therapeutics Holdings  (NAS:COAG) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Hemab Therapeutics Holdings's Inventory Turnover for the three months ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0.075 / 0
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Hemab Therapeutics Holdings's Inventory to Revenue for the three months ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Hemab Therapeutics Holdings Days Inventory Related Terms

Hemab Therapeutics Holdings Days Inventory Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Days Inventory Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Days Inventory
- -

Hemab Therapeutics Holdings Quarterly Data
Mar25 Jun25 Mar26 Jun26
Days Inventory - - - -

COAG vs ADMA, VCEL, KLRA: Days Inventory Comparison

For the Biotechnology subindustry, Hemab Therapeutics Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemab Therapeutics Holdings Days Inventory vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Days Inventory distribution charts can be found below:

* The bar in red indicates where Hemab Therapeutics Holdings's Days Inventory falls into.


COAG
12GF Score
Hemab Therapeutics Holdings Inc COAG
Days Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Hemab Therapeutics Holdings's Days Inventory for the fiscal year that ended in Dec. 2025 is calculated as

Days Inventory (A: Dec. 2025 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0 + 0) / 1 ) / 0.304*365
=0 / 0.304*365
=0.00

Hemab Therapeutics Holdings's Days Inventory for the quarter that ended in Jun. 2026 is calculated as:

Days Inventory (Q: Jun. 2026 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Mar. 2026 ) + Total Inventories (Q: Jun. 2026 )) / count ) / Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=( (0 + 0) / 1 ) / 0.075*365 / 4
=0 / 0.075*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
12GF Score

Get the complete analysis for COAG

Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.19
Price